Paul Hawthorne, Eisai's EVP, purpose and chief business officer, offers insight into building a market for Leqembi, Eisai's pricing and commercial strategy, and the challenges and opportunities in Alzheimer's disease.
- 1 In 300 People In The U.S. Is Living With HIV. That’s Not Okay With Jeff Galvin.
- How To Address ESG Risks Arising From Antimicrobial Resistance
- Dynavax’s Evolving Business Model
- Where Are They Now? Ono Pharmaceuticals
- The Ozempic Dilemma: What Makes A Dual Brand Approach Viable?
- Innovation From Animals And Evolution
- Empress Builds Base for Small-Molecule Innovation
- Companies to Watch: Promontory Therapeutics
COMPANIES TO WATCH
Companies to Watch: Promontory Therapeutics
A novel small molecule developer aims to shake up the solid tumor treatment landscape.
Founded in late 2019, KeifeRx is repurposing oncology drugs for neurodegenerative disorders.
Freya Biosciences is enlivening the long-time lonely space of reproductive health, starting with a new focus on the vaginal microbiome.
Spruce Biosciences is currently in mid-to-late stage clinical development of new agents to treat rare endocrine disorders.
WHERE ARE THEY NOW
Where Are They Now? Ono Pharmaceuticals
Ono Pharmaceuticals continues its quest to become a global biopharmaceutical company, after discovering and helping to launch one of the most successful cancer drugs, Opdivo, in the last decade.
Where Are They Now? Roivant
"Where Are They Now?" looks back, and forward, at companies and executives previously covered in Life Science Leader magazine.
Where Are They Now? Karuna Therapeutics
A new series from Life Science Leader looks backward, and forward, at the biopharmaceutical companies that have previously appeared in the pages of Life Science Leader magazine.